



February 16, 2021

U.S. Department of Health & Human Services (DHHS) &  
Department of Health Resources and Services Administration (HRSA)  
c/o Ms. Tamara Overby, Acting Director  
Division of Injury Compensation Programs (DICP)  
5600 Fishers Lane, 08N146B  
Rockville, MD 20857

Email: [toverby@hrsa.gov](mailto:toverby@hrsa.gov)

Official Comment Submission: [Regulations.gov](https://www.regulations.gov)

Re: Federal Register Docket No. HRSA-2021-0001 – National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table; Notice of Proposed Rulemaking; Public Comment Period; Delay of Effective Date. Document Citation 86 FR 9308.

The National Vaccine Information Center (NVIC) submits this additional written public comment in response to the above referenced Delay of Effective Date.<sup>1</sup> published in the *Federal Register*. NVIC continues its opposition to the proposed changes of removing shoulder injury related to vaccine administration (SIRVA) and syncope from the federal Vaccine Injury Table (VIT) in the national Vaccine Injury Compensation Program (VICP) for the reasons outlined below.

Additionally, NVIC appreciates this review of the final rule and additional opportunity to provide comment. We encourage HRSA and DHHS to again review our initial public comment on the NPRM submitted on January 12, 2021, as well as our comments contained herein, and seriously consider striking down this rule.

### **Background - NVIC's History with the National Childhood Vaccine Injury Act of 1986 (1986 Act)**

As noted in our initial public comment on Jan. 12, 2021,<sup>2</sup> NVIC has unique standing to provide comments on the VICP due to the work of NVIC's cofounders with Congress to draft and pass the National Childhood Vaccine Injury Act of 1986, which created the VICP and the VIT.

As previously stated, the Act's legislative history demonstrates that Congress intended to make vaccine safety a priority by including vaccine safety informing, recording, reporting and research provisions in the law, and also to protect the national childhood

vaccine supply by providing parents with a no-fault, less adversarial, less expensive and expedited administrative alternative to a vaccine injury lawsuit, which would help maintain parental trust in and support for the childhood vaccination program.

### **DHHS Final Rule Comments and Interpretation of the 1986 Act Remains Faulty**

While DHHS has the legal ability to remove SIRVA and syncope from the VIT, doing so violates the spirit and intent of the law, which was to give the benefit of doubt to plaintiffs and to avoid compelling the majority of petitioners to prove “causation in fact” for what are known today as off-table injuries.

With regard to the 1986 Act’s intent, when the VICP was first implemented, 74 percent of injury claims were for children with acknowledged vaccine injuries listed on the VIT. By 2015, that number had dwindled to two percent, while the number of off-table claims had skyrocketed to 98 percent.<sup>3</sup>

Data presented by DHHS to the Advisory Commission on Childhood Vaccines (ACCV) demonstrates that since the inclusion of SIRVA and syncope in 2017 on the VIT, the majority of petitions (54 percent) filed with the VICP have been for SIRVA injuries.<sup>4 5 6</sup>

The removal of these injuries from the Table will reverse the course of the Act’s legal intent of expanding the VIT to expedite compensation, which in essence implements avoidance of “causation in fact” cases.

As noted in our previous comment,<sup>7</sup> the Act does not preclude injuries resulting from vaccine administration,<sup>8 9</sup> a point that DHHS agreed with in 2009 with their addition of injection related injuries to the list of adverse events for review by the Institute of Medicine (IOM).<sup>10</sup> The list was based on petitioner claims to the VICP,<sup>11 12</sup> and DHHS explicitly stated they had searched the VICP database and found 13 cases of SIRVA, of which 12 were considered valid injuries.<sup>13 14</sup>

Respectfully, the response by DHHS in the final rule regarding these facts is inconsistent, revisionist, and lacks scientific justification for proceeding with this rule.<sup>15</sup>

### **Evidence Base for SIRVA and Syncope**

Though there has been a long-standing trend of a continued lack of high quality scientific research and/or absence of research to inform vaccine injury,<sup>16 17</sup> in their 2012 report, *Adverse Events Associated with Childhood Vaccines: Evidence and Causality*, the IOM found strong biological mechanism evidence<sup>18</sup> to support a causal relationship between the injection of vaccines for the requested outcomes of syncope and SIRVA.<sup>19</sup> Additionally, the IOM did not rule out the ingredients in vaccines themselves as being involved in the biological mechanisms for these injuries, contrary to statements within the NPRM.<sup>20 21 22</sup>

These findings were presented to the ACCV by DHHS and the IOM with encouragement for their inclusion within the VIT multiple times between the issuing of the IOM report up to the formal rule issued by DHHS in January 2017.<sup>23 24</sup>

As NVIC noted previously, during 2020 and the NPRM process, numerous health care professionals also expressed support for retaining SIRVA on the VIT based on their clinical experience<sup>25 26</sup> with some noting that the injection of other medications or blood products into the bursa or joint do not cause SIRVA like injuries and provided the evidence base for consideration.<sup>27</sup>

The Vaccine Injured Petitioners Bar Association also provided written comments on the NPRM noting that studies, which DHHS cites in the NPRM as supporting the removal of these injuries, in fact provided evidence that antigens in the vaccines may well be responsible for the development of SIRVA.<sup>28 29</sup>

NVIC also provided additional information relating to syncopal episodes post vaccination<sup>30 31</sup> and noted that the Centers for Disease Control (CDC) currently states that with regard to syncope, the role of vaccines has not been ruled out.<sup>32</sup> Notably, the VIT definition of SIRVA states that vaccine antigens may have a role in the development of SIRVA.<sup>33</sup>

Regarding DHHS's general process of basing changes to the VIT on scientific evidence, DHHS has failed to follow its previous process of presenting evidence to the ACCV,<sup>34 35 36 37 38 39 40</sup> as well as failing to request a review of evidence<sup>41</sup> that has occurred since 2009 when the IOM was first requested by DHHS to consider injection-related injuries. It is clear that DHHS has not only switched its position, but has done so in a manner that lacks integrity and fails to provide transparency.

To all appearances, this rule-making process has deliberately skirted the intent of the Act and abused the authority given to DHHS, due to the failure to transparently engage, consider, explore and present the scientific evidence base, particularly given DHHS's history in advocating for integration of these injuries into the Table. DHHS's characterization of the ACCV's fact-based objection to the removal of these injuries as being "not adequately persuasive"<sup>42</sup> rings hollow, given the lack of effort on DHHS' part to provide scientific evidence to justify their actions.

### **SIRVA, Syncope Removal from VIT will Increase Workloads and VICP Program Costs**

The intent of the Act, as noted earlier, was a less adversarial no-fault administrative compensation process that avoided petitioners being forced to hire an attorney to prove vaccine injury in the U.S. Court of Federal Claims.<sup>43</sup>

Reports from the General Accounting Office in 1999 and 2014 note that narrowing of the VIT creates an adversarial process and shifts the burden to the petitioner, making it harder to be compensated for vaccine injuries.<sup>44 45</sup>

While government and public health officials are concerned about "vaccine hesitancy" with regard to both federal routinely recommended vaccines<sup>46</sup> and COVID-19 vaccines,<sup>47</sup> implementation of this rule will not only increase hesitancy, but continue to take the VICP further away from the spirit and intent of the 1986 Act. It is clear that the enactment of this rule will fail to adequately inform the VIT or special masters adjudicating VICP claims, will fail to provide expeditious vaccine injury compensation to

plaintiffs with SIRVA and syncope injuries, and will provide no relief to VICP caseloads.<sup>48 49</sup>

NVIC strongly encourages DHHS to reverse this rule, which was aggressively pursued and implemented in the last days of the previous Administration, and take steps to restore the VICP to the original intent of the 1986 Act.

Sincerely,



Barbara Loe Fisher  
Co-founder & President



Theresa K. Wrangham  
Executive Director

## References

<sup>1</sup> Health Resources and Services Administration (HRSA) and Department of Health and Human Services (DHHS). [National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table: Notice of Proposed Rulemaking; Public Comment Period; Delay of Effective Date](#). *Federal Register* Feb. 12, 2021; Docket No. HRSA-2021-000, Citation 86 FR 9308.

<sup>2</sup> Fisher BL, Wrangham TK. [NVIC Written Public Comment - Notice of Proposed Rule Change - National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table](#). *National Vaccine Information Center (NVIC)* Jan. 12, 2021.

<sup>3</sup> Engstrom NF. [A Dose of Reality for Specialized Courts: Lessons from the VICP](#). *University of Pennsylvania Law Review* 2015; 163: pp. 1702-1703.

<sup>4</sup> Overby T. [Division of Injury Compensation Programs Update to ACCV](#). HRSA Mar. 6, 2020; Slide 11.

<sup>5</sup> Overby T. [Division of Injury Compensation Programs Update to ACCV](#). HRSA Sept. 4, 2020; Slide 11.

<sup>6</sup> Overby T. [Division of Injury Compensation Programs Update to ACCV](#). HRSA Dec. 3, 2020; Slide 11.

<sup>7</sup> Fisher BL, Wrangham TK. [NVIC Written Public Comment - Notice of Proposed Rule Change - National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table](#). *NVIC* Jan. 12, 2021.

<sup>8</sup> [42 U.S.C. §§ 300aa-11. Petitions for compensation](#). 2016 edition. *U.S. Government Publishing Office (GPO)*.

<sup>9</sup> GPO. [42 U.S.C. §§ 300aa-11. Petitions for compensation](#). 2016 edition.

<sup>10</sup> Johann-Liang R. [Updating the Vaccine Injury Table following the 2011 IOM Report on Adverse Effects of Vaccines](#). HRSA Mar. 8, 2012.

<sup>11</sup> Institute of Medicine (IOM). [Charge to the Committee](#). In: *Adverse Events of Vaccines: Causality Assessment*. *The National Academies Press* 2012; Pg. 30.

<sup>12</sup> Advisory Commission on Childhood Vaccines (ACCV). [Institute of Medicine Project of Vaccines and Adverse Events presented by Kathleen Stratton, Ph.D., Study Director, IOM](#). In: *ACCV Minutes*. HRSA Nov. 18, 2008; Pg. 15.

<sup>13</sup> ACCV. [Meeting Transcript](#). HRSA Mar. 8, 2012; Pg. 148.

<sup>14</sup> IOM. [TABLE 12-1 Summary of Epidemiologic Assessments, Mechanistic Assessments, and Causality Conclusions for Injection-Related Adverse Events](#). In: *Adverse Events of Vaccines: Causality Assessment*. *The National Academies Press* 2012; Pg. 619.

<sup>15</sup> HRSA & DHHS. [Section IV – General Concerns](#). In: *National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table – Final Rule*. *Federal Register* Jan. 21, 2021; Citation 86 FR 9308.

<sup>16</sup> IOM. [Afterword on Research Needs](#). In: *Adverse Effects of Pertussis and Rubella Vaccines*. *The National Academies Press* 1991; Pg. 206.

<sup>17</sup> National Vaccine Advisory Committee (NVAC). [White Paper on the United State Vaccine Safety System](#). *DHHS* September 2011; Pg. 43.

- 
- <sup>18</sup> IOM. [TABLE 12-1 Summary of Epidemiologic Assessments, Mechanistic Assessments, and Causality Conclusions for Injection-Related Adverse Events](#). In: Adverse Events of Vaccines: Evidence and Causality. *The National Academies Press* 2012; Pg. 625.
- <sup>19</sup> Johann-Liang R. [Updating the Vaccine Injury Table following the 2011 IOM Report on Adverse Effects of Vaccines](#). *HRSA* Mar. 8, 2012.
- <sup>20</sup> HRSA & DHHS. [Notice of Proposed Rule-Making - National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table](#). *Federal Register* Jul. 20, 2020; Citation 85 FR 43794.
- <sup>21</sup> Wrangham TK. [NPRM to Remove SIRVA and Syncope - Consumer Perspective](#). *NVIC* Dec. 3, 2020.
- <sup>22</sup> [TABLE 12-1 Summary of Epidemiologic Assessments, Mechanistic Assessments, and Causality Conclusions for Injection-Related Adverse Events](#). In: Adverse Events of Vaccines: Causality Assessment. *The National Academies Press* 2012; Pg. 619.
- <sup>23</sup> ACCV. [Meeting Transcript](#). *HRSA* Mar. 8, 2012; Pg. 148.
- <sup>24</sup> DHHS. [National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table](#). *Federal Register* Jan. 19, 2017; Citation 82 FR 6294.
- <sup>25</sup> ACCV. [Minutes](#). *HRSA* May, 18, 2020.
- <sup>26</sup> Srikumaran, U. [Open Letter to the Secretary - RE: National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table; Notice of Proposed Rulemaking](#). *HRSA* Mar. 26, 2020.
- <sup>27</sup> ACCV. [Minutes](#). *HRSA* May, 18, 2020.
- <sup>28</sup> Ciampolillo C. [Vaccine Injured Petitioners Bar Association Letter to ACCV - Health Resources and Services Administration \(HRSA\) Notice of Proposed Rulemaking \(NPRM\)](#). *HRSA* May 14, 2020.
- <sup>29</sup> Ryan, T. [2011 Institute of Medicine \(IOM\) Report generated Proposals for Updates to the Vaccine Injury Table \(VIT\) by the Injection-Related Work Group](#). *HRSA* Mar. 8, 2012.
- <sup>30</sup> NVIC. [Vaccine Safety Group Releases Gardasil Reaction Report - Calls on FDA and CDC to Warn Doctors and Parents to Report to VAERS](#). Feb. 21, 2007.
- <sup>31</sup> NVIC. [Analysis Shows Greater Risk of GBS Reports](#). Aug. 15, 2007.
- <sup>32</sup> CDC. [Vaccine Safety – Fainting after Vaccination](#). Aug. 25, 2020.
- <sup>33</sup> HRSA. [Federal Vaccine Injury Table](#). Mar. 27, 2017; Pg. 8.
- <sup>34</sup> Ryan T. [2011 Institute of Medicine \(IOM\) Report generated Proposals for Updates to the Vaccine Injury Table \(VIT\) by the Injection-Related Work Group](#). *HRSA* Mar. 8, 2012.
- <sup>35</sup> Ryan T. [Institute of Medicine \(IOM\) Report generated Proposals for Updates to the Vaccine Injury Table \(VIT\)](#). *HRSA* Dec. 9, 2011.
- <sup>36</sup> Houston AM. [Clarification on Proposed Changes to the Vaccine Injury Table](#). *HRSA* Sep. 4, 2014.
- <sup>37</sup> Dalle-Tezze T. [Prevention of SIRVA](#). *HRSA* Jun. 4, 2015.
- <sup>38</sup> ACCV. [SIRVA](#). In: ACCV Minutes. *HRSA* Jun. 3, 2016. Pg. 5.
- <sup>39</sup> DHHS. [National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table](#). *Federal Register* Jan. 19, 2017.
- <sup>40</sup> Wadman M. [United States wants to end most payouts for leading vaccination-related injury](#). *Science Magazine* Apr. 20, 2020.
- <sup>41</sup> GPO. [42 U.S.C. §§ 300aa-1. Establishment](#). 2016 edition.
- <sup>42</sup> HRSA & DHHS. [Section VIII – Miscellaneous Comments](#). In: National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table – Final Rule. *Federal Register* Jan. 21, 2021; Citation 86 FR 9308.
- <sup>43</sup> Wrangham TK. [Federal Government Poised to Expand Vaccine Injury Table](#). *NVIC Newsletter* May 9, 2012.
- <sup>44</sup> U.S. General Accounting Office (GAO). [Vaccine Injury Compensation - Program Challenged to Settle Claims Quickly and Easily](#). December 1999.
- <sup>45</sup> U.S. Government Accountability Office (GAO). [Vaccine Injury Compensation - Most Claims Took Multiple Years and Many Were Settled through Negotiation](#). November 2014.
- <sup>46</sup> DHHS. [Featured Priority: Vaccine Confidence](#): Vaccines & Immunizations. Aug. 6, 2019.
- <sup>47</sup> CDC COVID-19 Response Vaccine Task Force. [Building Confidence in COVID-19 Vaccines Among Your Patients – Tips for the Healthcare Team](#). *Centers for Disease Control* January 2021; Slide 15.
- <sup>48</sup> ACCV. [Minutes](#). *HRSA* Mar. 6, 2020; Pg. 2.
- <sup>49</sup> Overby T. [Division of Injury Compensation Programs Update to ACCV](#). *HRSA* Dec. 3, 2020; Slide 8.